11.20.2006, 09:48 AM
FRANKFURT (AFX) - Stada Arzneimittel AG said it is no longer to pursue its Interferon-beta project to treat multiple sclerosis, as limited marketing opportunities did not justify completion of the project.
The company said that the project, which was launched in 2001, did not have a completion date or a potential peak sales figure.
The move is part of the company's reorganisation of its Biosimilar projects.
Stada announced that it is now focusing on its Epo-zeta and Filgrastim projects.
The company is to transfer development, manufacturing and distribution rights for Epo-zeta for the US and Canada to US-based competitor Hospira.
Hospira is also to be granted distribution rights for Epo-zeta in the EU, said Stada.
Stada said that its milestone payments from Hospira would increase to 42.9 mln eur from 16.4 mln.
The company added that it continues to hold an option from 2011 for the complete takeover of Bioceuticals, of which it owns a 14.99 pct stake.
krysia.diver@afxnews.com
kd/cmr
Copyright AFX News Limited 2006. All rights reserved.
The copying, republication or redistribution of AFX News Content, including by framing or similar means, is expressly prohibited without the prior written consent of AFX News.
AFX News and AFX Financial News Logo are registered trademarks of AFX News Limited
Neither the Subscriber nor AFX News warrants the completeness or accuracy of the Service or the suitability of the Service as a trading aid and neither accepts any liability for losses howsoever incurred. The content on this site, including news, quotes, data and other information, is provided by AFX News and its third party content providers for your personal information only, and neither AFX News nor its third party content providers shall be liable for any errors, inaccuracies or delays in content, or for any actions taken in reliance thereon.
